Skip to main content

Vaginal Candidiasis

0
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
1 program
Metronidazole/MiconazoleN/ASmall Molecule1 trial
Active Trials
NCT01335373Completed13,024Est. Apr 2015
Peptonic Medical
Peptonic MedicalSweden - Stockholm
1 program
VagiVitalACN/A1 trial
Active Trials
NCT05012852Unknown126Est. Jun 2022
Alliance Pharmaceuticals
1 program
VagiVitalACN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Peptonic MedicalVagiVitalAC
BayerMetronidazole/Miconazole

Clinical Trials (2)

Total enrollment: 13,150 patients across 2 trials

Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis

Start: Sep 2021Est. completion: Jun 2022126 patients
N/AUnknown
NCT01335373BayerMetronidazole/Miconazole

Observational Program Neo-Penotran® Forte

Start: Oct 2010Est. completion: Apr 201513,024 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.